Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Durvalumab Plus Chemo Sustains 3-Year OS Benefit in Advanced Biliary Tract Cancer

April 16th 2024

Durvalumab plus chemotherapy produced superior 3-year survival outcomes vs chemotherapy alone in advanced biliary tract cancer.

Trajectory of Evolving HCC Treatment Landscape

April 15th 2024

The expert panelists provide their final insights surrounding the future of HCC treatment management.

REGONEXT Study: Driving Second-line HCC Treatment Strategy

April 15th 2024

Dr Morse discusses key takeaways from the REGONEXT study presented at ASCO GI 2024.

March Approval Madness: OncLive’s Roundup of FDA Decisions in Oncology

April 13th 2024

In case you missed it, these were the key regulatory decisions made by the FDA in March 2024.

Patient Case 2: A 62-Year-Old Woman with Metastatic Rectal Cancer

April 11th 2024

John Strickler, MD, presents the case of a 62-year-old woman with rectal cancer, and Arvind N. Dasari, MD, MS, provides clinical insights on his approach to third-line treatment with regorafenib, highlighting dose strategy and patient education.

Adverse Events Associated With TAS-102 Plus Bevacizumab in CRC

April 11th 2024

A panel of experts on colorectal cancer have a comprehensive discussion on adverse events associated with TAS-102 plus bevacizumab and strategies to mitigate them.

Dr Overman on Future Research Directions in GI Cancer

April 11th 2024

Michael J. Overman, MD, discusses future research directions in gastrointestinal cancers.

Insider Insights: Unveiling Takeaways from AACR 2024

April 11th 2024

Experts from across the oncology field highlight their biggest takeaways and the hottest topics from the 2024 AACR Annual Meeting.

CAN-2409 Receives FDA Orphan Drug Designation in Pancreatic Cancer

April 11th 2024

CAN-2409 has received orphan drug designation from the FDA for the treatment of patients with pancreatic cancer.

Dr Sahin on the Design of the Northstar Response Assay in Advanced GI Cancer

April 10th 2024

Ilyas Sahin, MD, discusses the Northstar Response assay and the future of precision oncology in patients with advanced gastrointestinal cancer.

Dr Overman on Nonoperative Cancer Management in GI Malignancies

April 9th 2024

Michael J. Overman, MD, discusses the rationale for utilizing a nonoperative management approach over traditional surgery in gastrointestinal cancers.

CARES-310 Trial: Impressions and Clinical Impact on HCC Treatment Landscape

April 8th 2024

Key opinion leaders share their takeaways from the CARES-310 trial and its impact on their treatment approach in HCC management.

Patient Profile 2: Patient Progression After Frontline HCC Therapy

April 8th 2024

Drs Saeed and Shroff discuss the next patient profile, focusing on HCC treatment strategies following disease progression after first-line therapy.

Combining Liver-directed and Systemic Therapies in HCC

April 8th 2024

The impact of compounding liver-directed and systemic therapies in HCC management is discussed by Drs Morse and Covey.

Cadonilimab Plus Oxaliplatin and Capecitabine Offers Survival Benefit in Gastric/GEJ Cancer

April 7th 2024

Cadonilimab plus oxaliplatin and capecitabine leads to survival benefit in gastric/GEJ adenocarcinoma, regardless of PD-L1 expression.

Iglesia Spotlights the Current Complexities of Treatment Sequencing in Advanced HCC

April 5th 2024

Michael Iglesia, MD, PhD, discusses the effects of the phase 3 CELESTIAL trial on treatment sequencing strategies in advanced hepatocellular carcinoma.

Dr Shah on 5-Year Outcomes With Pembrolizumab/Chemo in Esophageal Cancer

April 5th 2024

Manish A. Shah, MD, discusses 5-year outcomes from the KEYNOTE-590 trial of frontline pembrolizumab plus chemotherapy in patients with esophageal cancer.

CAN-2409 Plus Valacyclovir Generates Positive Phase 2 Survival Results in PDAC

April 4th 2024

Positive phase 2 findings for CAN-2409 plus valacyclovir in pancreatic ductal adenocarcinoma have been reported.

FDA to Review Zanidatamab BLA for HER2+ Metastatic Biliary Tract Cancer

April 2nd 2024

A rolling BLA for zanidatamab in previously treated, HER2-positive, advanced biliary tract cancer has been submitted to the FDA.

Dr Pedersen on the Evolution of Immunotherapy in HCC

April 1st 2024

Katrina S. Pedersen, MD, MS, discusses the evolution of the role of immunotherapy in the treatment of patients with hepatocellular carcinoma.